TY - JOUR
T1 - Nanomedicine in the treatment of Alzheimer’s disease
T2 - bypassing the blood-brain barrier with cutting-edge nanotechnology
AU - Dong, Nana
AU - Ali-Khiavi, Payam
AU - Ghavamikia, Nima
AU - Pakmehr, Seyed Abbas
AU - Sotoudegan, Farzaneh
AU - Hjazi, Ahmed
AU - Gargari, Morad Kohandel
AU - Gargari, Homa Kohandel
AU - Behnamrad, Parisa
AU - Rajabi, Mohammadreza
AU - Elhami, Anis
AU - Saffarfar, Hossein
AU - Nourizadeh, Mehrdad
N1 - Publisher Copyright:
© Fondazione Società Italiana di Neurologia 2024.
PY - 2025/4
Y1 - 2025/4
N2 - Alzheimer’s disease (AD) remains a formidable challenge in the field of neurodegenerative disorders, necessitating innovative therapeutic strategies. Nanomedicine, leveraging nanomaterials, has emerged as a promising avenue for AD treatment, with a key emphasis on overcoming the blood-brain barrier (BBB) to enhance drug delivery efficiency. This review provides a comprehensive analysis of recent advancements in the application of nanomaterials for AD therapy, highlighting their unique properties and functions. The blood-brain barrier, a complex physiological barrier, poses a significant hurdle for traditional drug delivery to the brain. Nanomedicine addresses this challenge by utilizing various nanomaterials such as liposomes, polymeric nanoparticles, and metal nanoparticles. These nanocarriers enable improved drug bioavailability, sustained release, and targeted delivery to specific brain regions affected by AD pathology. The review discusses the diverse range of nanomaterials employed in AD treatment, exploring their capacity to encapsulate therapeutic agents, modulate drug release kinetics, and enhance drug stability. Additionally, the multifunctionality of nanomaterials allows for simultaneous imaging and therapy, facilitating early diagnosis and intervention. Key aspects covered include the interaction of nanomaterials with Aβ aggregates, the role of antioxidants in mitigating oxidative stress, and the potential of nanomedicine in alleviating neuroinflammation associated with AD. Furthermore, the safety, biocompatibility, and toxicity profiles of various nanomaterials are scrutinized to ensure their clinical applicability. In conclusion, this review underscores the pivotal role of nanomedicine and nanomaterials in revolutionizing AD treatment strategies. By specifically addressing BBB challenges, these innovative approaches offer new avenues for targeted drug delivery and improved therapeutic outcomes in the complex landscape of Alzheimer’s disease.
AB - Alzheimer’s disease (AD) remains a formidable challenge in the field of neurodegenerative disorders, necessitating innovative therapeutic strategies. Nanomedicine, leveraging nanomaterials, has emerged as a promising avenue for AD treatment, with a key emphasis on overcoming the blood-brain barrier (BBB) to enhance drug delivery efficiency. This review provides a comprehensive analysis of recent advancements in the application of nanomaterials for AD therapy, highlighting their unique properties and functions. The blood-brain barrier, a complex physiological barrier, poses a significant hurdle for traditional drug delivery to the brain. Nanomedicine addresses this challenge by utilizing various nanomaterials such as liposomes, polymeric nanoparticles, and metal nanoparticles. These nanocarriers enable improved drug bioavailability, sustained release, and targeted delivery to specific brain regions affected by AD pathology. The review discusses the diverse range of nanomaterials employed in AD treatment, exploring their capacity to encapsulate therapeutic agents, modulate drug release kinetics, and enhance drug stability. Additionally, the multifunctionality of nanomaterials allows for simultaneous imaging and therapy, facilitating early diagnosis and intervention. Key aspects covered include the interaction of nanomaterials with Aβ aggregates, the role of antioxidants in mitigating oxidative stress, and the potential of nanomedicine in alleviating neuroinflammation associated with AD. Furthermore, the safety, biocompatibility, and toxicity profiles of various nanomaterials are scrutinized to ensure their clinical applicability. In conclusion, this review underscores the pivotal role of nanomedicine and nanomaterials in revolutionizing AD treatment strategies. By specifically addressing BBB challenges, these innovative approaches offer new avenues for targeted drug delivery and improved therapeutic outcomes in the complex landscape of Alzheimer’s disease.
KW - Alzheimer’s disease
KW - Blood-brain barrier
KW - Nanomaterials
KW - Nanomedicine
KW - Nanoparticles
UR - http://www.scopus.com/inward/record.url?scp=85211376096&partnerID=8YFLogxK
U2 - 10.1007/s10072-024-07871-4
DO - 10.1007/s10072-024-07871-4
M3 - Review article
C2 - 39638950
AN - SCOPUS:85211376096
SN - 1590-1874
VL - 46
SP - 1489
EP - 1507
JO - Neurological Sciences
JF - Neurological Sciences
IS - 4
ER -